Balance Sheet Components

9 Months Ended

Sep. 30, 2021

Balance Sheet Related Disclosures [Abstract]

Note 3—Balance Sheet Components

Prepaid expenses and other current assets consisted of the following (in thousands):

	September 30, 2021		December 31, 2020
Prepaid research and development	$	5,500	$	2,462
Prepaid bonus		800		409
Prepaid clinical trial		779		944
Prepaid insurance		144		2,480
Other		1,162		331
Total prepaid expenses and other current assets	$	8,385	$	6,626

Property, plant and equipment consisted of the following (in thousands):

	September 30, 2021			December 31, 2020
Leasehold improvements	$	1,876		$	—
Furniture and fixtures		759			—
Computer equipment		818			95
Laboratory equipment		476			—
Construction in progress		36,916			201
		40,845			296
Accumulated depreciation		(292	)		(9	)
Property, plant and equipment, net	$	40,553		$	287

Included in construction in progress at September 30, 2021 was $36.7 million of costs associated with the Build-to-Suit lease (see Note 11).

Depreciation expense was $166,000 and $283,000 for the three and nine months ended September 30, 2021, respectively. Depreciation expense was not significant for the three and nine months ended September 30, 2020.

Accrued expenses and other current liabilities consisted of the following (in thousands):

	September 30, 2021		December 31, 2020
Accrued research and development	$	9,330	$	2,106
Accrued compensation		5,752		1,766
Accrued professional and consulting fees		1,386		999
Accrued property, plant, and equipment		2,774		173
Accrued clinical trial		1,142		—
Other		779		91
Total accrued expenses and other current liabilities	$	21,163	$	5,135